» Articles » PMID: 38523785

Multi-modality Deep Learning Model Reaches High Prediction Accuracy in the Diagnosis of Ovarian Cancer

Overview
Journal iScience
Publisher Cell Press
Date 2024 Mar 25
PMID 38523785
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated the diagnostic performance of a multimodal deep-learning (DL) model for ovarian mass differential diagnosis. This single-center retrospective study included 1,054 ultrasound (US)-detected ovarian tumors (699 benign and 355 malignant). Patients were randomly divided into training (n = 675), validation (n = 169), and testing (n = 210) sets. The model was developed using ResNet-50. Three DL-based models were proposed for benign-malignant classification of these lesions: single-modality model that only utilized US images; dual-modality model that used US images and menopausal status as inputs; and multi-modality model that integrated US images, menopausal status, and serum indicators. After 5-fold cross-validation, 210 lesions were tested. We evaluated the three models using the area under the curve (AUC), accuracy, sensitivity, and specificity. The multimodal model outperformed the single- and dual-modality models with 93.80% accuracy and 0.983 AUC. The Multimodal ResNet-50 DL model outperformed the single- and dual-modality models in identifying benign and malignant ovarian tumors.

Citing Articles

Multimodal deep learning approaches for precision oncology: a comprehensive review.

Yang H, Yang M, Chen J, Yao G, Zou Q, Jia L Brief Bioinform. 2025; 26(1).

PMID: 39757116 PMC: 11700660. DOI: 10.1093/bib/bbae699.


Deep learning radiomics on grayscale ultrasound images assists in diagnosing benign and malignant of BI-RADS 4 lesions.

Yang L, Zhang N, Jia J, Ma Z Sci Rep. 2024; 14(1):31479.

PMID: 39733121 PMC: 11682229. DOI: 10.1038/s41598-024-83347-x.


Development and validation of a deep learning pipeline to diagnose ovarian masses using ultrasound screening: a retrospective multicenter study.

Dai W, Wu Y, Ling Y, Zhao J, Zhang S, Gu Z EClinicalMedicine. 2024; 78:102923.

PMID: 39640935 PMC: 11617315. DOI: 10.1016/j.eclinm.2024.102923.


Predict value of tumor markers combined with interleukins for therapeutic efficacy and prognosis in ovarian cancer patients.

Cheng F, Ma X, Cheng Z, Wang Y, Zhang X, Ma C Am J Cancer Res. 2024; 14(10):4868-4879.

PMID: 39553206 PMC: 11560821. DOI: 10.62347/GSRD2580.

References
1.
Goff B, Agnew K, Neradilek M, Gray H, Liao J, Urban R . Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol Oncol. 2017; 147(2):291-295. DOI: 10.1016/j.ygyno.2017.08.020. View

2.
Christiansen F, Epstein E, Smedberg E, Akerlund M, Smith K, Epstein E . Ultrasound image analysis using deep neural networks for discriminating between benign and malignant ovarian tumors: comparison with expert subjective assessment. Ultrasound Obstet Gynecol. 2020; 57(1):155-163. PMC: 7839489. DOI: 10.1002/uog.23530. View

3.
Wang H, Liu C, Zhao Z, Zhang C, Wang X, Li H . Application of Deep Convolutional Neural Networks for Discriminating Benign, Borderline, and Malignant Serous Ovarian Tumors From Ultrasound Images. Front Oncol. 2022; 11:770683. PMC: 8720926. DOI: 10.3389/fonc.2021.770683. View

4.
Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

5.
LeCun Y, Bengio Y, Hinton G . Deep learning. Nature. 2015; 521(7553):436-44. DOI: 10.1038/nature14539. View